EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study

Byeong Geun Song, Myeongcheol Lee, Juhee Cho, Geum-Youn Gwak, Danbee Kang, Dong Hyun Sinn

Liver Cancer · 29.06.2026 · 1-11

DOI: 10.1159/000553325 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver Cancer, online erschienen am 29.06.2026. Verfasst von Byeong Geun Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Beta-blockers reduce portal hypertension; however, evidence comparing carvedilol and propranolol in patients with hepatocellular carcinoma (HCC) is lacking. We aimed to compare the clinical outcomes of carvedilol versus propranolol in patients with HCC.

Methods

Using the Korean National Health Insurance Service database (2009–2023), we identified 11,124 patients with newly diagnosed HCC who were prescribed either carvedilol (n = 2,457) or propranolol (n = 8,667) within 180 days of diagnosis. The primary outcome was all-cause mortality, and the secondary outcome was hepatic decompensation. Multivariable Cox regression and 1:2 PS matching were used as primary analytical approaches, with sensitivity analyses restricted to 6-month survivors and a new-user design.

Results

During a median follow-up of 1.5 years, carvedilol use was associated with a significantly lower risk of hepatic decompensation (adjusted hazard ratio [aHR] 0.67; 95% confidence interval [CI] 0.62–0.72) and all-cause mortality (aHR 0.84; 95% CI 0.79–0.90) compared to propranolol. In the 1:2 PS-matched cohort (n = 5,922), these associations remained consistent for both decompensation (HR 0.68; 95% CI 0.63–0.74) and mortality (HR 0.84; 95% CI 0.78–0.90). These benefits were consistent across various subgroups, and in sensitivity analysis excluding early death within 6 months from diagnosis and using a new-user design.

Conclusion

In patients with HCC, carvedilol was associated with better survival and lower risk of hepatic decompensation than propranolol. Carvedilol may be the preferred beta-blocker over propranolol in the setting of HCC.

Schlagwörter

Stichwörter der Autor:innen

CarvedilolHepatocellular carcinomaHypertensionPortalPropranolol

Autor:innen und Institutionen

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
  • Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Trend Sensing and Risk Modeling Center, Institution of Cancer Quality of Life, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Zitieren

APA

Song, B. G., Lee, M., Cho, J., Gwak, G. Y., Kang, D., & Sinn, D. H. (2026). Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study. Liver Cancer, 1-11. https://doi.org/10.1159/000553325

Vancouver

Song BG, Lee M, Cho J, Gwak GY, Kang D, Sinn DH. Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study. Liver Cancer. 2026:1-11. doi:10.1159/000553325

BibTeX
@article{Song2026,
  author = {Song, Byeong Geun and Lee, Myeongcheol and Cho, Juhee and Gwak, Geum-Youn and Kang, Danbee and Sinn, Dong Hyun},
  title = {Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study},
  journal = {Liver Cancer},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000553325}
}
Kostenlos starten →